• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >The good, the bad and the ugly: how altered peptide ligands modulate immunity.
【24h】

The good, the bad and the ugly: how altered peptide ligands modulate immunity.

机译：好的，坏的和丑陋的：改变的肽配体如何调节免疫力。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The basis of T cell immune responses is the specific recognition of an immunogenic peptide epitope by a T cell receptor. Peptide alterations of such T cell epitopes with single or few amino acid variations can have drastic effects on the outcome of this recognition. These altered peptide ligands can act as modulators of immune responses as they are capable of downregulating or upregulating responses. OBJECTIVE/METHODS: We review how altered peptide ligands can have 'good' 'bad' and 'ugly' outcomes in treating diseases. RESULTS/CONCLUSION: Altered peptide ligands have been used as immunotherapeutics in autoimmune (and allergic) diseases, infectious diseases and cancer. In the next five years we anticipate seeing a number of altered peptide ligands in clinical trials, progressing from contradictory classifications of good, bad or ugly, to the exciting outcome of 'useful'.
机译：背景：T细胞免疫应答的基础是T细胞受体对免疫原性肽表位的特异性识别。具有单个或很少的氨基酸变异的此类T细胞表位的肽改变可能对这种识别的结果产生重大影响。这些改变的肽配体可作为免疫应答的调节剂，因为它们能够下调或上调应答。目的/方法：我们综述了改变的肽配体在治疗疾病中如何产生“好”，“坏”和“丑陋”的结果。结果/结论：改变的肽配体已被用作自身免疫性（和过敏性）疾病，传染病和癌症的免疫疗法。在未来五年中，我们预计在临床试验中会看到许多肽配体发生变化，从好，坏或丑陋的相互矛盾的分类发展到令人兴奋的“有用”结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号